Cardiac amyloidosis is an often-missed, life-threatening cause of heart failure. As new disease-modifying therapies emerge, ...

Background Heart failure with preserved ejection fraction (HFpEF) is a complex clinical syndrome in which signs and symptoms of heart failure (HF) occur despite a normal left ventricular ejection ...

The heterogeneity of patients with the same diagnostic label, lack of unified diagnostic criteria and limited treatment options have resulted in patients receiving inconsistent care. It is with these ...

Exclusion criteria were known heart failure, left ventricular ejection fraction <50% or valve abnormality >mild in severity. Median follow-up was 5.6 (IQR 4.6–6.3) years.Results Median time to heart ...

Aim As heart failure (HF) with preserved ejection fraction (HFpEF) prevalence increases, it remains frequently underdiagnosed and poorly managed. Recent positive pharmacological trials have increased ...

HEART failure with preserved ejection fraction (HFpEF) is present in 74% of patients with severe isolated secondary tricuspid regurgitation (TR), but had been previously identified in only 35%, ...

Methods Current criteria for the diagnosis of HFpEF (evidence of symptoms or signs of heart failure, EF>50%, abnormal transmitral flow and supplementary tissue Doppler measurements (E/e′) suggesting ...

Multiple measures of RV function during exercise, including markers of RV-PA coupling, were improved with dapagliflozin. “Remarkably, one-third of patients treated with dapagliflozin no longer met ...

Although heart failure with preserved ejection fraction (HFpEF) has become the predominant heart failure subtype, it remains clinically under-recognized. HFpEF diagnosis is particularly challenging in ...

BACKGROUND: Although heart failure with preserved ejection fraction (HFpEF) has become the predominant heart failure subtype, it remains clinically under-recognized. HFpEF diagnosis is particularly ...